Trials / Completed
CompletedNCT03452345
MEDITOXIN® Treatment in Subject With Benign Masseteric Hypertrophy
A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of MEDOTIXN® in Subject With Benign Masseteric Hypertrophy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 180 (actual)
- Sponsor
- Medy-Tox · Industry
- Sex
- All
- Age
- 20 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of MEDITOXIN in subjects with benign masseteric hypertrophy compared with placebo
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Meditoxin | Meditoxin (Botulinum toxin type A) |
| DRUG | Placebo | Placebo (Normal saline) |
Timeline
- Start date
- 2018-04-09
- Primary completion
- 2019-01-31
- Completion
- 2019-04-16
- First posted
- 2018-03-02
- Last updated
- 2020-07-28
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03452345. Inclusion in this directory is not an endorsement.